Halogen atoms are widely used in drug molecules to improve their binding affinity for the receptor proteins. Many of the examples involve “halogen bonding” between the molecule and the binding site, which is a directional interaction between a halogen atom and a nucleophilic atom. Such an interaction is induced by an electron cloud shift of the halogen atom toward its covalently bonded neighbor to form the σ-bond, leaving a small electrostatic positive region opposite to the bond called the “σ-hole.” To mimic the effect of the σ-hole in the CHARMM non-polarizable force field, recently CGenFF added a positively charged massless particle to halogen atoms, positioned at the opposite side of the carbon–halogen bond. This particle is referred to as a lone pair (LP) particle because it uses the lone pair implementation in the CHARMM force field. Here, we have added support for LP particles to ffTK, an automated force field parameterization toolkit widely distributed as a plugin to the molecular visualization software VMD. We demonstrate the updated optimization process using an example halogenated drug molecule, AT130, which is a capsid assembly modulator targeting the hepatitis B virus. Our results indicate that parameterization with the LP particle significantly improves the accuracy of the electrostatic response of the molecule, especially around the halogen atom. Although the inclusion of the LP particle does not produce a prominent effect on the interactions between the molecule and its target protein, the protein–ligand binding performance is greatly improved by optimization of the parameters.
REFERENCES
1.
G.
Cavallo
, P.
Metrangolo
, R.
Milani
, T.
Pilati
, A.
Priimagi
, G.
Resnati
, and G.
Terraneo
, “The halogen bond
,” Chem. Rev.
116
, 2478
–2601
(2016
).2.
S.
Buchini
, A.
Buschiazzo
, and S. G.
Withers
, “A new generation of specific Trypanosoma cruzi trans-sialidase inhibitors
,” Angew. Chem., Int. Ed.
47
, 2700
–2703
(2008
).3.
A. C. L.
Leite
, D. R. d. M.
Moreira
, M. V. d. O.
Cardoso
, M. Z.
Hernandes
, V. R.
Alves Pereira
, R. O.
Silva
, A. C.
Kiperstok
, M. d. S.
Lima
, and M. B. P.
Soares
, “Synthesis, Cruzain docking, and in vitro studies of aryl-4-oxothiazolylhydrazones against Trypanosoma cruzi
,” ChemMedChem
2
, 1339
–1345
(2007
).4.
B. L.
Grasberger
, T.
Lu
, C.
Schubert
, D. J.
Parks
, T. E.
Carver
, H. K.
Koblish
, M. D.
Cummings
, L. V.
LaFrance
, K. L.
Milkiewicz
, R. R.
Calvo
, D.
Maguire
, J.
Lattanze
, C. F.
Franks
, S.
Zhao
, K.
Ramachandren
, G. R.
Bylebyl
, M.
Zhang
, C. L.
Manthey
, E. C.
Petrella
, M. W.
Pantoliano
, I. C.
Deckman
, J. C.
Spurlino
, A. C.
Maroney
, B. E.
Tomczuk
, C. J.
Molloy
, and R. F.
Bone
, “Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells
,” J. Med. Chem.
48
, 909
–912
(2005
).5.
D. J.
Parks
, L. V.
Lafrance
, R. R.
Calvo
, K. L.
Milkiewicz
, V.
Gupta
, J.
Lattanze
, K.
Ramachandren
, T. E.
Carver
, E. C.
Petrella
, M. D.
Cummings
, D.
Maguire
, B. L.
Grasberger
, and T.
Lu
, “1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: Discovery and SAR
,” Bioorg. Med. Chem. Lett.
15
, 765
–770
(2005
).6.
O.
Fedorov
, K.
Huber
, A.
Eisenreich
, P.
Filippakopoulos
, O.
King
, A. N.
Bullock
, D.
Szklarczyk
, L. J.
Jensen
, D.
Fabbro
, J.
Trappe
, U.
Rauch
, F.
Bracher
, and S.
Knapp
, “Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing
,” Chem. Biol.
18
, 67
–76
(2011
).7.
L. A.
Hardegger
, B.
Kuhn
, B.
Spinnler
, L.
Anselm
, R.
Ecabert
, M.
Stihle
, B.
Gsell
, R.
Thoma
, J.
Diez
, J.
Benz
, J.-M.
Plancher
, G.
Hartmann
, Y.
Isshiki
, K.
Morikami
, N.
Shimma
, W.
Haap
, D. W.
Banner
, and F.
Diederich
, “Halogen bonding at the active sites of human cathepsin L and MEK1 kinase: Efficient interactions in different environments
,” ChemMedChem
6
, 2048
–2054
(2011
).8.
Á. M.
Montaña
, “The σ and π holes. the halogen and tetrel bondings: Their nature, importance and chemical, biological and medicinal implications
,” ChemistrySelect
2
, 9094
–9112
(2017
).9.
M. R.
Scholfield
, C. M. V.
Zanden
, M.
Carter
, and P. S.
Ho
, “Halogen bonding (X-bonding): A biological perspective
,” Protein Sci.
22
, 139
–152
(2013
).10.
K.
Naumann
, “Influence of chlorine substituents on biological activity of chemicals
,” J. Prakt. Chem.
341
, 417
–435
(1999
).11.
K.
Vanommeslaeghe
, E.
Hatcher
, C.
Acharya
, S.
Kundu
, S.
Zhong
, J.
Shim
, E.
Darian
, O.
Guvench
, P.
Lopes
, I.
Vorobyov
, and A. D.
MacKerell
, Jr., “CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields
,” J. Comput. Chem.
31
, 671
–690
(2010
).12.
W. D.
Cornell
, P.
Cieplak
, C. I.
Bayly
, I. R.
Gould
, K. M.
Merz
, D. M.
Ferguson
, D. C.
Spellmeyer
, T.
Fox
, J. W.
Caldwell
, and P. A.
Kollman
, “A second generation force field for the simulation of proteins, nucleic acids, and organic molecules
,” J. Am. Chem. Soc.
117
, 5179
–5197
(1995
).13.
W. L.
Jorgensen
and J.
Tirado-Rives
, “The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin
,” J. Am. Chem. Soc.
110
, 1657
–1666
(1988
).14.
W. L.
Jorgensen
, J.
Chandrasekhar
, J. D.
Madura
, R. W.
Impey
, and M. L.
Klein
, “Comparison of simple potential functions for simulating liquid water
,” J. Chem. Phys.
79
, 926
–935
(1983
).15.
W. R.
Scott
, P. H.
Hünenberger
, I. G.
Tironi
, A. E.
Mark
, S. R.
Billeter
, J.
Fennen
, A. E.
Torda
, T.
Huber
, P.
Krüger
, and W. F.
van Gunsteren
, “The GROMOS software for biomolecular simulation: GROMOS05
,” J. Comput. Chem.
26
, 1719
–1751
(2005
).16.
A. N. S.
Adluri
, J. N.
Murphy
, T.
Tozer
, and C. N.
Rowley
, “Polarizable force field with a σ-hole for liquid and aqueous bromomethane
,” J. Phys. Chem. B
119
, 13422
–13432
(2015
).17.
I.
Soteras Gutiérrez
, F.-Y.
Lin
, K.
Vanommeslaeghe
, J. A.
Lemkul
, K. A.
Armacost
, C. L.
Brooks
, and A. D.
MacKerell
, Jr., “Parametrization of halogen bonds in the CHARMM general force field: Improved treatment of ligand-protein interactions
,” Bioorg. Med. Chem.
24
, 4812
–4825
(2016
).18.
E.
Harder
, W.
Damm
, J.
Maple
, C.
Wu
, M.
Reboul
, J. Y.
Xiang
, L.
Wang
, D.
Lupyan
, M. K.
Dahlgren
, J. L.
Knight
, J. W.
Kaus
, D. S.
Cerutti
, G.
Krilov
, W. L.
Jorgensen
, R.
Abel
, and R. A.
Friesner
, “OPLS3: A force field providing broad coverage of drug-like small molecules and proteins
,” J. Chem. Theory Comput.
12
, 281
–296
(2016
).19.
M. A. A.
Ibrahim
, “Molecular mechanical study of halogen bonding in drug discovery
,” J. Comput. Chem.
32
, 2564
–2574
(2011
).20.
M. A. A.
Ibrahim
, “Molecular mechanical perspective on halogen bonding
,” J. Mol. Model.
18
, 4625
–4638
(2012
).21.
X.
Mu
, Q.
Wang
, L.-P.
Wang
, S. D.
Fried
, J.-P.
Piquemal
, K. N.
Dalby
, and P.
Ren
, “Modeling organochlorine compounds and the σ-hole effect using a polarizable multipole force field
,” J. Phys. Chem. B
118
, 6456
–6465
(2014
).22.
F.-Y.
Lin
and A. D.
MacKerell
, Jr., “Do halogen–hydrogen bond donor interactions dominate the favorable contribution of halogens to ligand–protein binding?
,” J. Phys. Chem. B
121
, 6813
–6821
(2017
).23.
F.-Y.
Lin
and A. D.
MacKerell
, Jr., “Improved modeling of halogenated ligand-protein interactions using the Drude polarizable and CHARMM additive empirical force fields
,” J. Chem. Inf. Model.
59
, 215
–228
(2019
).24.
C. G.
Mayne
, J.
Saam
, K.
Schulten
, E.
Tajkhorshid
, and J. C.
Gumbart
, “Rapid parameterization of small molecules using the force field toolkit
,” J. Comput. Chem.
34
, 2757
–2770
(2013
).25.
J. C.
Gumbart
, M.
Beeby
, G. J.
Jensen
, and B.
Roux
, “Escherichia coli peptidoglycan structure and mechanics as predicted by atomic-scale simulations
,” PLoS Comput. Biol.
10
, e1003475
(2014
).26.
A.
Pavlova
and J. C.
Gumbart
, “Parametrization of macrolide antibiotics using the force field toolkit
,” J. Comput. Chem.
36
, 2052
–2063
(2015
).27.
L.
Han
, L.
Yan
, M.
Wang
, K.
Wang
, L.
Fang
, J.
Zhou
, J.
Fang
, F.
Ren
, and X.
Lu
, “Transparent, adhesive, and conductive hydrogel for soft bioelectronics based on light-transmitting polydopamine-doped polypyrrole nanofibrils
,” Chem. Mater.
30
, 5561
–5572
(2018
).28.
Y.-C.
Chiang
, O.
Levsh
, C. K.
Lam
, J.-K.
Weng
, and Y.
Wang
, “Structural and dynamic basis of substrate permissiveness in hydroxycinnamoyltransferase (HCT)
,” PLoS Comput. Biol.
14
, e1006511
(2018
).29.
Q.
Chen
, M. M.
Wells
, P.
Arjunan
, T. S.
Tillman
, A. E.
Cohen
, Y.
Xu
, and P.
Tang
, “Structural basis of neurosteroid anesthetic action on GABAA receptors
,” Nat. Commun.
9
, 3972
(2018
).30.
J. A.
Coleman
, D.
Yang
, Z.
Zhao
, P.-C.
Wen
, C.
Yoshioka
, E.
Tajkhorshid
, and E.
Gouaux
, “Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport
,” Nature
569
, 141
–145
(2019
).31.
Y.-C.
Chiang
, M. T.
Wong
, and J. W.
Essex
, “Molecular dynamics simulations of antibiotic ceftaroline at the allosteric site of penicillin-binding protein 2a (PBP2a)
,” Isr. J. Chem.
60
, 754
–763
(2020
).32.
J. J.
Feld
, D.
Colledge
, V.
Sozzi
, R.
Edwards
, M.
Littlejohn
, and S. A.
Locarnini
, “The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging
,” Antiviral Res.
76
, 168
–177
(2007
).33.
K.
Deres
, C. H.
Schröder
, A.
Paessens
, S.
Goldmann
, H. J.
Hacker
, O.
Weber
, T.
Krämer
, U.
Niewöhner
, U.
Pleiss
, J.
Stoltefuss
et al, “Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids
,” Science
299
, 893
–896
(2003
).34.
C.
Bourne
, S.
Lee
, B.
Venkataiah
, A.
Lee
, B.
Korba
, M. G.
Finn
, and A.
Zlotnick
, “Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle
,” J. Virol.
82
, 10262
–10270
(2008
).35.
W. E.
Delaney
, R.
Edwards
, D.
Colledge
, T.
Shaw
, P.
Furman
, G.
Painter
, and S.
Locarnini
, “Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro
,” Antimicrob. Agents Chemotheraphy
46
, 3057
–3060
(2002
).36.
M. R.
Campagna
, F.
Liu
, R.
Mao
, C.
Mills
, D.
Cai
, F.
Guo
, X.
Zhao
, H.
Ye
, A.
Cuconati
, H.
Guo
, J.
Chang
, X.
Xu
, T. M.
Block
, and J.-T.
Guo
, “Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids
,” J. Virol.
87
, 6931
–6942
(2013
).37.
Z.
Zhou
, T.
Hu
, X.
Zhou
, S.
Wildum
, F.
Garcia-Alcalde
, Z.
Xu
, D.
Wu
, Y.
Mao
, X.
Tian
, Y.
Zhou
, F.
Shen
, Z.
Zhang
, G.
Tang
, I.
Najera
, G.
Yang
, H. C.
Shen
, J. A.
Young
, and N.
Qin
, “Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms
,” Sci. Rep.
7
, 42374
(2017
).38.
O.
Sari
, S.
Boucle
, B. D.
Cox
, T.
Ozturk
, O. O.
Russell
, L.
Bassit
, F.
Amblard
, and R. F.
Schinazi
, “Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector
,” Eur. J. Med. Chem.
138
, 407
–421
(2017
).39.
A. G.
Cole
, “Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection
,” Curr. Opin. Pharmacol.
30
, 131
–137
(2016
).40.
L.
Yang
, F.
Liu
, X.
Tong
, D.
Hoffmann
, J.
Zuo
, and M.
Lu
, “Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: Recent advances and perspectives
,” ACS Infect. Dis.
5
, 713
–724
(2019
).41.
W.
Humphrey
, A.
Dalke
, and K.
Schulten
, “VMD: Visual molecular dynamics
,” J. Mol. Graphics
14
, 33
–38
(1996
).42.
K.
Vanommeslaeghe
and A. D.
MacKerell
, Jr., “Automation of the CHARMM general force field (CGenFF) I: Bond perception and atom typing
,” J. Chem. Inf. Model.
52
, 3144
–3154
(2012
).43.
K.
Vanommeslaeghe
, E. P.
Raman
, and A. D.
MacKerell
, Jr., “Automation of the CHARMM general force field (CGenFF) II: Assignment of bonded parameters and partial atomic charges
,” J. Chem. Inf. Model.
52
, 3155
–3168
(2012
).44.
M.
Frisch
, G.
Trucks
, H.
Schlegel
, G.
Scuseria
, M.
Robb
, J.
Cheeseman
, G.
Scalmani
, V.
Barone
, G.
Petersson
, H.
Nakatsuji
et al, Gaussian 16, revision A. 03, Gaussian, Inc.
, Wallingford, CT
, 2016
.45.
F.
Neese
, “The ORCA program system
,” Wiley Interdiscip. Rev.: Comput. Mol. Sci.
2
, 73
–78
(2012
).46.
J. C.
Phillips
, R.
Braun
, W.
Wang
, J.
Gumbart
, E.
Tajkhorshid
, E.
Villa
, C.
Chipot
, R. D.
Skeel
, L.
Kalé
, and K.
Schulten
, “Scalable molecular dynamics with NAMD
,” J. Comput. Chem.
26
, 1781
–1802
(2005
).47.
J. A.
Nelder
and R.
Mead
, “A simplex method for function minimization
,” Comput. J.
7
, 308
–313
(1965
).48.
W. H.
Press
, S. A.
Teukolsky
, W. T.
Vetterling
, and B. P.
Flannery
, Numerical Recipes in C
, 2nd ed. (Cambridge University Press
, New York
, 1992
).49.
A. V.
Marenich
, C. J.
Cramer
, and D. G.
Truhlar
, “Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions
,” J. Phys. Chem. B
113
, 6378
–6396
(2009
).50.
J. C.
Phillips
, D. J.
Hardy
, J. D. C.
Maia
, J. E.
Stone
, J. V.
Ribeiro
, R. C.
Bernardi
, R.
Buch
, G.
Fiorin
, J.
Hénin
, W.
Jiang
, R.
McGreevy
, M. C. R.
Melo
, B. K.
Radak
, R. D.
Skeel
, A.
Singharoy
, Y.
Wang
, B.
Roux
, A.
Aksimentiev
, Z.
Luthey-Schulten
, L. V.
Kalé
, K.
Schulten
, C.
Chipot
, and E.
Tajkhorshid
, “Scalable molecular dynamics on CPU and GPU architectures with NAMD
,” J. Chem. Phys.
153
, 044130
(2020
).51.
J.
Huang
, S.
Rauscher
, G.
Nawrocki
, T.
Ran
, M.
Feig
, B. L.
de Groot
, H.
Grubmüller
, and A. D.
MacKerell
, Jr., “CHARMM36m: An improved force field for folded and intrinsically disordered proteins
,” Nat. Methods
14
, 71
–73
(2017
).52.
S. E.
Feller
, Y.
Zhang
, R. W.
Pastor
, and B. R.
Brooks
, “Constant pressure molecular dynamics simulation: The Langevin piston method
,” J. Chem. Phys.
103
, 4613
–4621
(1995
).53.
T.
Darden
, D.
York
, and L.
Pedersen
, “Particle mesh Ewald: An N · log(N) method for Ewald sums in large systems
,” J. Chem. Phys.
98
, 10089
–10092
(1993
).© 2020 Author(s).
2020
Author(s)
You do not currently have access to this content.
